Sign In
Buy NXTC
$3.15
-0.250 (-7.35%)
At Close: Jun 03, 2026
NextCure to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
01:00pm, Monday, 22'nd Nov 2021 ForexTV
BELTSVILLE, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in the Piper Sandler Virtual 32nd Annual Healthcare Conference on November 30th. An audio webcast of the pre-recorded The post NextCure to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference appeared first on ForexTV .
NextCure to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
08:00am, Monday, 22'nd Nov 2021
BELTSVILLE, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin
2 Net Current Asset Value Stocks to Consider
11:00am, Friday, 29'th Oct 2021
There are some investors who buy U.S.-listed stocks that are trading below their liquidation values because they believe they can gain a lot from these stocks after the market has reappraised the shar
NextCure Announces Three New Members of its Scientific Advisory Board
08:05am, Tuesday, 19'th Oct 2021
BELTSVILLE, Md., Oct. 19, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin
NextCure Announces Publication of Preclinical Data for NC410
04:05pm, Thursday, 07'th Oct 2021
BELTSVILLE, Md., Oct. 07, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedici
NextCure Announces New Appointments to its Board of Directors
08:05am, Monday, 04'th Oct 2021
BELTSVILLE, Md., Oct. 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin
NXTC Stock Price: Why It Increased Over 12%
02:54pm, Saturday, 02'nd Oct 2021
The stock price of NextCure Inc (NASDAQ: NXTC) increased by over 12% in the previous trading session. This is why it happened.
NextCure to Give Three Presentations at Society for Immunotherapy of Cancer Annual Meeting
08:45am, Friday, 01'st Oct 2021
BELTSVILLE, Md., Oct. 01, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedici
NextCure: Large Upside With Downside Protected By Cash Pile
08:07am, Wednesday, 29'th Sep 2021
The stock is left for dead, trading significantly below cash which creates a margin of safety. Significant data on all 3 drugs is due in the next 9 months.
NextCure to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
07:00am, Tuesday, 07'th Sep 2021
BELTSVILLE, Md., Sept. 07, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedici
NextCure Launches Early-Stage Study For NC762 In Solid Tumor Settings
08:06am, Wednesday, 07'th Jul 2021
NextCure Inc (NASDAQ: NXTC) has initiated the clinical trial of its third product candidate, NC762, a humanized B7-H4 monoclonal antibody. The Phase 1 dose-escalation portion of this Phase 1/2 open
NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors
04:05pm, Tuesday, 06'th Jul 2021
BELTSVILLE, Md., July 06, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat c
NextCure's Immunomedicine NC410 Shows Promising Anti-Cancer Activity In Preclinical Studies
06:34am, Tuesday, 22'nd Jun 2021
NextCure Inc (NASDAQ: NXTC) has published preclinical data for NC410 in the online journal eLife. NC410 is currently being evaluated in a Phase 1/2 trial in patients with advanced or metastatic sol
NextCure and Collaborators Publish Preclinical Data on Novel Immunomedicine NC410
04:05pm, Monday, 21'st Jun 2021
BELTSVILLE, Md., June 21, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat c
NextCure to Present at the JMP Securities Life Sciences Conference
04:10pm, Thursday, 10'th Jun 2021
BELTSVILLE, Md., June 10, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin
